FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	D.C. 20549
---------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Scalzo Richard William					2. Issuer Name and Ticker or Trading Symbol <u>Dyne Therapeutics</u> , <u>Inc.</u> [DYN]									(Che	ck all applic Directo	able)	g Pers	son(s) to Iss 10% Ov Other (s	ner	
(Last) (First) (Middle) C/O DYNE THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 07/11/2022									X	below) See Rem			below) ks			
1560 TRAPELO ROAD					4 If Amandment Date of Original Filed (Marth/Day 2/2-2)									6 Individual or Inint/Crown Filing (Charle A1						
(Street) WALTH	WALTHAM MA 02451				4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				ction 2A. Deemed Execution Date,			3. Transact Code (In:	tion str.	4. Securities Acquired (A Disposed Of (D) (Instr. 3, r. 5)		ed (A) tr. 3, 4	or	5. Amour Securitie Beneficia	nt of 6. O es Forr ally (D) o Following d tion(s)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise (Instr. 3) Price of Derivative Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year)				Co	ansacti de (Ins	on of Der Sec Acc (A) Dis of (ı of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		rity	B. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i i illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode V	(A)			Date Exercisable		xpiration ate	Title	Amo or Num of Shar	ber						
Stock Option (right to buy)	\$8.58	07/11/2022		I	A .	55,0	000		(1)	0	7/10/2032	Common Stock	55,0	000	\$0.00	55,000	0	D		

Explanation of Responses:

1. This option was granted on July 11, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments from July 1, 2022.

Remarks:

Senior Vice President of Accounting and Administration and Treasurer

07/13/2022 /s/ Richard Scalzo

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.